Expert Analysis

Metastatic Breast Cancer

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Metastatic Breast Cancer

Faculty:

Clifford A. Hudis, MD
Kathy D. Miller, MD
Joyce O’Shaughnessy, MD

CREDIT INFORMATION

Release Date: March 10, 2008

Expiration Date: March 09, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the use of breast surgery for patients with metastatic breast cancer
Describe chemotherapy combinations used in the treatment of metastatic breast cancer
Cite study results regarding biologic agents used in combination with chemotherapy to treat patients with breast cancer

Topics covered include:

Surgery for Women Presenting With Stage IV Breast Cancer
Capecitabine/Paclitaxel vs Epirubicin/Paclitaxel for High-Risk Metastatic Breast Cancer
Gemcitabine/Docetaxel vs Capecitabine/Docetaxel for Anthracycline-Pretreated Metastatic Breast Cancer
Docetaxel Every 3 Weeks vs Weekly Docetaxel in Anthracycline-Resistant Metastatic Breast Cancer
Docetaxel Plus Bevacizumab for the First-Line Treatment of HER2-Negative Metastatic Breast Cancer
E2103: Trastuzumab, Ixabepilone, and Carboplatin in Previously Untreated HER2+ Metastatic Breast Cancer
Pertuzumab/Trastuzumab Following Progression on Trastuzumab Therapy
Trastuzumab After the Onset of Breast Cancer Brain Metastases
Ixabepilone Plus Capecitabine in Anthracycline and/or Taxane-Resistant MBC
Trastuzumab-DM1 in Patients With Advanced HER2+ Breast Cancer
E2100: Genetic Polymorphisms in Vascular Endothelial Growth Factor
Irinotecan/Carboplatin With or Without Cetuximab in Patients With Metastatic Breast Cancer
Cetuximab in Triple-Negative Metastatic Breast Cancer
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.